2029 Clinical Development Disease Pharma Companies 
Vial
MARCH 1, 2024
The growing demand for CRO services is fueled by the high costs of in-house drug discovery and development, the increasing number of products in the development pipeline, tech advancements, and the growing focus on precision and personalized medicine. billion by 2029. from 2024 to reach US$129.8 completed its acquisition of PPD.
Drug Discovery World
OCTOBER 4, 2022
This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. This year has seen some major deals announced by big pharma companies.
Expert insights. Personalized for you.
52 
Let's personalize your content